Media Resources

Media Kit

Company Logos

Executive Leadership Bios

Arthur Kuan –
Chairman & CEO

Ambaw Bellete –
President & COO
Vijay Kasturi,
MD – CMO
Swapnil Bhargava –
CTO
Corleen Roche profile picture

Corleen Roche –
CFO

Corleen Roche profile picture

Josh Patterson, Esq. –
General Counsel & CCO

Mechanism of Action Images

0. CG_Oncology-MoA_info

1. NMIBC tumor cross section of the bladder Ta.T1 and CIS

2. Cretostimogene grenadenorepvec an oncolytic immunotherapy (OIT)
3. Cretostimogene grenadenorepvec an oncolytic immunotherapy (OIT)
4. Cretostimogene grenadenorepvec instillation in the bladder over a CIS tumor
5. Cretostimogene grenadenorepvec attaching to a CAR receptor
6. E2F promoter is permanently activated in cancer cells: cancer cells and health cells

7. Retinoblastoma and P53 proteins

8. Immune cells activated in tumor microenvironment: lysing the tumor

9. Additional cretostimogene grenadenorepvec progeny being released
10. CG Oncology – MoA – For presentation